By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
MedsparkMedsparkMedspark
  • Home
  • News & Alerts
    News & AlertsShow More
    A Shanghai lab turns its whole bench over to AI agents
    By
    msadmin
    November 5, 2026
    Britain’s Sovereign AI bets seed money on physics instead of wet labs
    By
    msadmin
    November 5, 2026
    AI measures heart function more consistently than expert readers
    By
    msadmin
    November 5, 2026
    AstraZeneca tests AI on the tissue slides that decide drug safety
    By
    msadmin
    November 5, 2026
    Evident Vascular clears FDA hurdle with a fully AI native IVUS console
    By
    msadmin
    November 5, 2026
  • Spotlight
    SpotlightShow More
    Robinhood Ventures Fund II brings retail capital to healthcare AI
    By
    msadmin
    August 13, 2026
    Adialante brings accessible MRI-based cancer screening
    By
    msadmin
    August 11, 2026
    CellType models biology so AI can discover drugs
    By
    msadmin
    August 11, 2026
    Healthcare AI startups in Robinhood Ventures Fund II
    By
    msadmin
    August 11, 2026
    OpenAI launches GPT-Rosalind for life sciences research
    By
    msadmin
    July 17, 2026
  • Articles
    ArticlesShow More
    Singapore clinics let an AI watch for referrals nobody ever sent
    By
    msadmin
    November 1, 2026
    An AI team of agents grades immunotherapy side effects
    By
    msadmin
    October 30, 2026
    Brain implant decoders fail when patients or hardware change, review warns
    By
    msadmin
    October 25, 2026
    Proteomics model picks breast cancer drugs from biopsies
    By
    msadmin
    September 10, 2026
    CRISP model reads frozen sections to steer cancer surgery
    By
    msadmin
    September 10, 2026
  • About
    • Mission
    • Services
    • Contact
  • Shop
    • All Items
    • By Category
    • Cart
  • Newsletter
Font ResizerAa
MedsparkMedspark
Font ResizerAa
  • Home
  • News & Alerts
  • Spotlight
  • Articles
  • About
  • Shop
  • Newsletter
  • Home
  • News & Alerts
  • Spotlight
  • Articles
  • About
    • Mission
    • Services
    • Contact
  • Shop
    • All Items
    • By Category
    • Cart
  • Newsletter
Follow US
News & Alerts

Raygun AI resizes natural proteins without losing their function

Duke University's Raygun AI can shrink or enlarge natural proteins without breaking their shape, opening new options for biologic drug design.

MedSpark Staff
By
msadmin
MedSpark Staff
Bymsadmin
Medical, Healthcare, & Biotech/Pharma AI News
Follow:
Published: August 1, 2026
Share
2 Min Read
SHARE

A Duke University team has built an AI called Raygun that can make a natural protein smaller or larger while keeping its folded shape and its working behavior intact, a trick they say could hand biotech better-behaved versions of molecules already in use.

Raygun rests on ESM-2, a protein language model schooled on millions of amino-acid sequences. Where typical models dream up brand-new molecules, Raygun reshapes ones that already exist, borrowing tricks from evolution such as adding, deleting or swapping a single building block.

Earlier software that tried to resize real proteins typically ended up distorting them. Raygun avoids that by chopping a protein into segments, turning each segment into a numerical representation, then applying learned rules to reconstruct the protein at a new size while keeping its architecture sound, according to the team that includes computational biologist Rohit Singh.

The findings appeared in Nature on July 29. Fajie Yuan, a protein language model researcher at Westlake University who was not involved, welcomed the approach as a meaningful first step toward editing trusted proteins rather than starting from scratch.

The medical payoff could be significant. A smaller protein can fit into spaces a larger one cannot, and resized molecules may be easier to manufacture as biologics, antibodies and enzyme treatments. Refining existing proteins is also less risky than designing new ones from zero.

The bigger picture: protein AI is maturing from inventing molecules to fine-tuning familiar ones. Researchers expect that to matter for drug developers chasing biologics with better delivery, stability or tissue penetration.

TAGGED:AI Drug DiscoveryDuke UniversityESM-2Natureprotein designprotein engineeringRaygun
SOURCES:NatureNature Research Paper
Share This Article
Facebook Copy Link Print
MedSpark Staff
Bymsadmin
Follow:
Medical, Healthcare, & Biotech/Pharma AI News

You Might Also Like

News & Alerts

Takeda uses Weave Bio AI to draft drug filings 97% faster

By
msadmin
September 3, 2026
News & Alerts

Outro banks $7M to help patients taper off antidepressants

By
msadmin
October 14, 2026
News & Alerts

Cornell professors win FDA clearance for a brain artery reader

By
msadmin
October 29, 2026
News & Alerts

Medtronic backs Hong Kong robot maker with $700M for global sales

By
msadmin
September 3, 2026

AI news, analysis, and insights for healthcare, biotech, and pharma.

Facebook Twitter Youtube Linkedin
Quick Links
  • News & Alerts
  • Articles
  • Spotlight
  • Events
About Medspark
  • Mission
  • Services
  • Contact

© Copyright 2026 MedSpark. All rights reserved.

Privacy Policy | Legal